|
1
|
Roy R, Chun J and Powell SN: BRCA1 and
BRCA2: Different roles in a common pathway of genome protection.
Nat Rev Cancer. 12:68–78. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Powell SN and Kachnic LA: Roles of BRCA1
and BRCA2 in homologous recombination, DNA replication fidelity and
the cellular response to ionizing radiation. Oncogene.
22:5784–5791. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karami F and Mehdipour P: A comprehensive
focus on global spectrum of BRCA1 and BRCA2 mutations in breast
cancer. Biomed Res Int. 2013:9285622013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshida R: Hereditary breast and ovarian
cancer (HBOC): Review of its molecular characteristics, screening,
treatment, and prognosis. Breast Cancer. Aug 29–2020.(Epub ahead of
print). View Article : Google Scholar
|
|
5
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open. 2:e0001722017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Apostolou P and Fostira F: Hereditary
breast cancer: The era of new susceptibility genes. Biomed Res Int.
2013:7473182013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burgess M and Puhalla S: BRCA 1/2-mutation
related and sporadic breast and ovarian cancers: More alike than
different. Front Oncol. 4:192014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: a joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kauff ND, Satagopan JM, Robson ME, Scheuer
L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, et
al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or
BRCA2 mutation. N Engl J Med. 346:1609–1615. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
King MC, Wieand S, Hale K, Lee M, Walsh T,
Owens K, Tait J, Ford L, Dunn BK, Costantino J, et al: Tamoxifen
and breast cancer incidence among women with inherited mutations in
BRCA1 and BRCA2: National surgical adjuvant breast and bowel
project (NSABP-P1) breast cancer prevention trial. JAMA.
286:2251–2256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fattouh M, Ahmed H and Hafez Eel S:
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with
breast cancer and their relatives by PCR-SSCP method. Egypt J
Immunol. 18:9–16. 2011.PubMed/NCBI
|
|
12
|
Ibrahim SS, Hafez EE and Hashishe MM:
Presymptomatic breast cancer in Egypt: Role of BRCA1 and BRCA2
tumor suppressor genes mutations detection. J Exp Clin Cancer Res.
29:822010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Laraqui A, Uhrhammer N, Rhaffouli HE,
Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al
Bouzidi A, Bakri Y, et al: BRCA genetic screening in Middle Eastern
and North African: Mutational spectrum and founder BRCA1 mutation
(c.798_799delTT) in North African. Dis Markers. 2015:1942932015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim YC, Soliman AS, Cui J, Ramadan M,
Hablas A, Abouelhoda M, Hussien N, Ahmed O, Zekri AN, Seifeldin IA
and Wang SM: Unique features of germline variation in five Egyptian
familial breast cancer families revealed by exome sequencing. PLoS
One. 12:e01675812017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rebbeck TR, Friebel TM, Friedman E, Hamann
U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, et al:
Mutational spectrum in a worldwide study of 29,700 families with
BRCA1 or BRCA2 mutations. Hum Mutat. 39:593–620. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei H, Wang M, Ou J, Jiang W, Tian F,
Sheng Y, Li H, Xu H, Zhang R, Guan A, et al: Multicenter
cross-sectional screening of the BRCA gene for Chinese high
hereditary risk breast cancer populations. Oncol Lett.
15:9420–9428. 2018.PubMed/NCBI
|
|
17
|
Mesman RLS, Calléja FMGR, Hendriks G,
Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H and
Vreeswijk MPG: The functional impact of variants of uncertain
significance in BRCA2. Genet Med. 21:293–302. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fernandes VC, Golubeva VA, Di Pietro G,
Shields C, Amankwah K, Nepomuceno TC, de Gregoriis G, Abreu RBV,
Harro C, Gomes TT, et al: Impact of amino acid substitutions at
secondary structures in the BRCT domains of the tumor suppressor
BRCA1: Implications for clinical annotation. J Biol Chem.
294:5980–5992. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balabanski L, Antov G, Dimova I, Ivanov S,
Nacheva M, Gavrilov I, Nesheva D, Rukova B, Hadjidekova S, Malinov
M and Toncheva D: Next-generation sequencing of BRCA1 and BRCA2 in
breast cancer patients and control subjects. Mol Clin Oncol.
2:435–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Concolino P, Gelli G, Rizza R, Costella A,
Scambia G and Capoluongo E: BRCA1 and BRCA2 testing through next
generation sequencing in a small cohort of Italian breast/ovarian
cancer patients: Novel pathogenic and unknown clinical significance
variants. Int J Mol Sci. 20:34422019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lindor NM, Guidugli L, Wang X, Vallee MP,
Monteiro AN, Tavtigian S, Goldgar DE and Couch FJ: A review of a
multifactorial probability-based model for classification of BRCA1
and BRCA2 variants of uncertain significance (VUS). Hum Mutat.
33:8–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Konstantopoulou I, Tsitlaidou M, Fostira
F, Pertesi M, Stavropoulou AV, Triantafyllidou O, Tsotra E,
Tsiftsoglou AP, Tsionou C, Droufakou S, et al: High prevalence of
BRCA1 founder mutations in Greek breast/ovarian families. Clin
Genet. 85:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abbad A, Baba H, Dehbi H,
Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O and Radouani F: Genetics
of breast cancer in African populations: A literature review. Glob
Health Epidemiol Genom. 3:e82018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dines JN, Shirts BH, Slavin TP, Walsh T,
King MC, Fowler DM and Pritchard CC: Systematic misclassification
of missense variants in BRCA1 and BRCA2 ‘coldspots’. Genet Med.
22:825–830. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schroeder C, Stutzmann F, Weber BH, Riess
O and Bonin M: High-throughput resequencing in the diagnosis of
BRCA1/2 mutations using oligonucleotide resequencing microarrays.
Breast Cancer Res Treat. 122:287–297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borg A, Haile RW, Malone KE, Capanu M,
Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, et
al: Characterization of BRCA1 and BRCA2 deleterious mutations and
variants of unknown clinical significance in unilateral and
bilateral breast cancer: The WECARE study. Hum Mutat.
31:E1200–E1240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Forat-Yazdi M, Neamatzadeh H, Sheikhha MH,
Zare-Shehneh M and Fattahi M: BRCA1 and BRCA2 common mutations in
iranian breast cancer patients: A meta analysis. Asian Pac J Cancer
Prev. 16:1219–1224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang Y, Tian T, Yu C, Zhou W, Yang J,
Wang Y, Wen Y, Chen J, Dai J, Jin G, et al: Identification of
recurrent variants in BRCA1 and BRCA2 across multiple cancers in
the Chinese population. Biomed Res Int. 2020:67398232020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Wen WX, Eklund M, Kvist A, Eriksson
M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning
AM, Decker B, et al: Prevalence of BRCA1 and BRCA2 pathogenic
variants in a large, unselected breast cancer cohort. Int J Cancer.
144:1195–1204. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
AbdelHamid SG, Zekri AN, AbdelAziz HM and
El-Mesallamy HO: BRCA1 and BRCA2 truncating mutations and variants
of unknown significance in Egyptian female breast cancer patients.
Clin Chim Acta. 512:66–73. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eccles BK, Copson E, Maishman T, Abraham
JE and Eccles DM: Understanding of BRCA VUS genetic results by
breast cancer specialists. BMC Cancer. 15:9362015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arai M, Yokoyama S, Watanabe C, Yoshida R,
Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, et al:
Genetic and clinical characteristics in Japanese hereditary breast
and ovarian cancer: First report after establishment of HBOC
registration system in Japan. J Hum Genet. 63:447–457. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshida R, Watanabe C, Yokoyama S, Inuzuka
M, Yotsumoto J, Arai M and Nakamura S; Registration Committee of
the Japanese HBOC consortium, : Analysis of clinical
characteristics of breast cancer patients with the Japanese founder
mutation BRCA1 L63X. Oncotarget. 10:3276–3284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Palmero EI, Carraro DM, Alemar B, Moreira
MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, Galvão HCR, Reis RM, de
Pádua Souza C, Campacci N, et al: The germline mutational landscape
of BRCA1 and BRCA2 in Brazil. Sci Rep. 8:91882018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Slavin TP, Maxwell KN, Lilyquist J, Vijai
J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A,
Villano D, et al: The contribution of pathogenic variants in breast
cancer susceptibility genes to familial breast cancer risk. NPJ
Breast Cancer. 3:222017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Petrucelli N, Daly MB and Pal T: BRCA1-
and BRCA2-associated hereditary breast and ovarian cancer.
GeneReviews® [Internet]. Adam MP, Ardinger HH, Pagon RA,
Wallace SE, Bean LJH, Mirzaa G and Amemiya A: University of
Washington; Seattle, WA: 1993
|
